Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Market Closed 12-12 16:00:00 EST

49.80

+3.78

+8.21%

盘后49.70

-0.10-0.20%

19:49 EST

High50.16	Low45.45	Vol1.38M
Open45.93	D1 Closing46.02	Amplitude10.23%
Mkt Cap3.49B	Tradable Cap2.50B	Total Shares70.07M
T/O67.67M	T/O Rate2.76%	Tradable Shares50.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":49.8,"timestamp":1765573200000,"preClose":46.02,"halted":0,"volume":1384856,"hourTrading":{"tag":"盘后","latestPrice":49.7,"preClose":49.8,"latestTime":"19:49 EST","volume":14152,"amount":704777.3922,"timestamp":1765586963179},"delay":0,"floatShares":50198200,"shares":70066174,"eps":-3.99905,"marketStatus":"Market Closed","change":3.78,"latestTime":"12-12 16:00:00 EST","open":45.93,"high":50.16,"low":45.45,"amount":67665781.38144,"amplitude":0.102347,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.99905,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":46.02,"preHourTrading":{"tag":"盘前","latestPrice":46,"preClose":46.02,"latestTime":"09:01 EST","volume":162,"amount":7514.935866,"timestamp":1765548065444},"postHourTrading":{"tag":"盘后","latestPrice":49.7,"preClose":49.8,"latestTime":"19:49 EST","volume":14152,"amount":704777.3922,"timestamp":1765586963179},"volumeRatio":0.6730016732581413,"impliedVol":0.6644,"impliedVolPercentile":0.396},"requestUrl":"/m/hq/s/VERA/wiki","defaultTab":"wiki","newsList":[{"id":"2590514130","title":"Vera Therapeutics Is Maintained at Neutral by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2590514130","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590514130?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:36","pubTimestamp":1765463760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 09:36 ET (14:36 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"gpt_icon":0},{"id":"2590135435","title":"Vera Therapeutics Inc : Wedbush  Raises Target Price to $33 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2590135435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590135435?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:19","pubTimestamp":1765455558,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH10A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4588","BK4539","VERA"],"gpt_icon":0},{"id":"2590135905","title":"Wedbush Raises Price Target on Vera Therapeutics to $33 From $23, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590135905","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590135905?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:17","pubTimestamp":1765455479,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) has an average rating of buy and mean price target of $69.92, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA"],"gpt_icon":0},{"id":"2590558113","title":"Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558113","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558113?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400755,"startTime":"0","endTime":"0","summary":"William D. Turner, Chief Regulatory Officer of Vera Therapeutics Inc., reported a disposal of common shares of Vera Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL4GLBdt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4588","BK4139","BK4585","VERA"],"gpt_icon":0},{"id":"2590627300","title":"Vera Therapeutics Prices $261 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590627300","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590627300?lang=en_us&edition=fundamental","pubTime":"2025-12-10 17:09","pubTimestamp":1765357786,"startTime":"0","endTime":"0","summary":"Vera Therapeutics  said Tuesday that it has priced an underwritten public offering of about 6.1 million shares at $42.50 each.The gross proceeds are expected to be around $261 million, the company said.The offering is expected to close on Thursday.The company has also granted underwriters a 30-day option to purchase up to 920,716 additional shares.Shares of the company were down over 3% in recent premarket activity Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","VERA","BK4539","BK4585","BK4139"],"gpt_icon":0},{"id":"2590937919","title":"BRIEF-Vera Therapeutics Prices Public Offering Of Class A Common Stock At $42.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590937919","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590937919?lang=en_us&edition=fundamental","pubTime":"2025-12-10 10:00","pubTimestamp":1765332009,"startTime":"0","endTime":"0","summary":"BRIEF-Vera Therapeutics Prices Public Offering Of Class A Common Stock At $42.50 Per ShareDec 9 (Reuters) - Vera Therapeutics Inc VERA.O:VERA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF CLASS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA2SNQTN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","VERA","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2590637963","title":"Vera Therapeutics Inc - Prices Public Offering at $42.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590637963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590637963?lang=en_us&edition=fundamental","pubTime":"2025-12-10 09:58","pubTimestamp":1765331886,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA2SNQTN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4539","BK4139","VERA"],"gpt_icon":0},{"id":"2590379633","title":"Vera Therapeutics Announces Pricing of Public Offering of Class a Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2590379633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590379633?lang=en_us&edition=fundamental","pubTime":"2025-12-10 09:58","pubTimestamp":1765331886,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA2SNQTN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","BK4588","BK4585","VERA"],"gpt_icon":0},{"id":"2590010369","title":"Vera Therapeutics Plans Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590010369","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590010369?lang=en_us&edition=fundamental","pubTime":"2025-12-09 06:33","pubTimestamp":1765233239,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) said late Monday it plans a public offering of $200 million of class A common shares.The company will grant underwriters a 30-day overallotment option to buy up to an additional 15% of the shares, according to a statement.Vera shares fell 6.5% in after-hours trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","BK4539","VERA","BK4585"],"gpt_icon":0},{"id":"2590365638","title":"Vera Therapeutics Inc - Plans $200 Mln Public Offering of Class a Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365638?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:01","pubTimestamp":1765227660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA1KVTQN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","VERA","BK4588","BK4585"],"gpt_icon":0},{"id":"2590036550","title":"Press Release: Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2590036550","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590036550?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:01","pubTimestamp":1765227660,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Dec. 08, 2025  -- Vera Therapeutics, Inc. , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock. All of the shares are being offered by Vera Therapeutics.In connection with the proposed offering, Vera Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics' mission is to advance treatments that ta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","BK4539","VERA"],"gpt_icon":0},{"id":"2589855354","title":"Vera Therapeutics Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2589855354","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589855354?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:19","pubTimestamp":1765207140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 10:19 ET (15:19 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"gpt_icon":0},{"id":"2589658810","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589658810","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589658810?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:05","pubTimestamp":1764968700,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Dec.  05, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200976/0/en/Vera-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4539","BK4588","VERA"],"gpt_icon":0},{"id":"2589837530","title":"Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589837530","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589837530?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:06","pubTimestamp":1764882383,"startTime":"0","endTime":"0","summary":"William D. Turner, Chief Regulatory Officer of Vera Therapeutics Inc., reported a disposal of common shares of Vera Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4ycdh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4539","BK4585","VERA"],"gpt_icon":0},{"id":"2588041047","title":"Vera Therapeutics Inc : JP Morgan Raises Target Price to $99 From $52","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041047?lang=en_us&edition=fundamental","pubTime":"2025-12-03 23:20","pubTimestamp":1764775257,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90L8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","BK4539","BK4588","VERA"],"gpt_icon":0},{"id":"2588722693","title":"Will Vera Therapeutics (VERA) Strengthen Its Commercial Edge With Board Appointment of James R. Meyers?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722693","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722693?lang=en_us&edition=fundamental","pubTime":"2025-12-01 17:19","pubTimestamp":1764580763,"startTime":"0","endTime":"0","summary":"Vera Therapeutics recently announced the appointment of seasoned biopharmaceutical leader James R. Meyers to its Board of Directors as the company advances commercial readiness for its lead drug candidate atacicept in immunoglobulin A nephropathy (IgAN).\nThis move signals a focus on strengthening commercial capabilities as Vera prepares for potential regulatory approval and market entry of a first-in-class therapy.\nWe'll explore how leadership additions such as James R. Meyers' appointment...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/will-vera-therapeutics-vera-strengthen-its-commercial-edge-w","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/will-vera-therapeutics-vera-strengthen-its-commercial-edge-w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4539","BK4588","BK4585","VERA"],"gpt_icon":0},{"id":"2587555765","title":"A Fresh Look at Vera Therapeutics (VERA) Valuation as Analyst Optimism Follows Board Addition and FDA Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2587555765","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587555765?lang=en_us&edition=fundamental","pubTime":"2025-11-29 20:21","pubTimestamp":1764418896,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, the clinical-stage biotech, has been in focus this week as investors react to several key developments. The company’s recent board appointment and regulatory advances are drawing fresh attention to its commercialization strategy for new immunology treatments.\nSee our latest analysis for Vera Therapeutics.\nThe past month has seen Vera Therapeutics regain investor interest, with a 14.95% share price return over 30 days and a striking 55.96% return over 90 days. Momentum...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/a-fresh-look-at-vera-therapeutics-vera-valuation-as-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/a-fresh-look-at-vera-therapeutics-vera-valuation-as-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","DCF","BK4539","BK4585","VERA","BK4139"],"gpt_icon":0},{"id":"2586260928","title":"Vera Therapeutics Appoints James R. Meyers to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260928","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260928?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:05","pubTimestamp":1764191116,"startTime":"0","endTime":"0","summary":"Vera Therapeutics Inc. has appointed James R. Meyers, a veteran biopharmaceutical executive with extensive commercial leadership experience, to its Board of Directors. Meyers previously held key roles at Gilead Sciences and IntraBio Ltd., and currently serves on the boards of Sangamo Therapeutics, Inc. and CytomX Therapeutics, Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL4zD5dP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","IE00BKVL7J92.USD","BK4550","SGMO","LU0823416689.USD","LU1674673691.USD","BK4112","LU2089984988.USD","CTMX","LU2095319765.USD","BK4139","IE00B19Z3B42.SGD","IE00B64PRP62.GBP","NDAQ","LU0058720904.USD","LU2087621335.USD","LU1430594728.SGD","BK4556","SG9999015945.SGD","IE00BSNM7G36.USD","LU1674673428.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU1066053197.SGD","BK4566","LU2210150020.SGD","LU0114720955.EUR","SG9999015978.USD","IE00BKPKM429.USD","BK4583","LU1585245621.USD","LU0109394709.USD","IE0002270589.USD","BK4539","SG9999015986.USD","IE00B19Z3581.USD","LU1839511570.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","IE00B3QW5Z07.USD","GILD","LU0289739699.SGD","LU0320765992.SGD","BK4578","LU0889565916.HKD","LU1066051498.USD","LU2324357040.USD","VERA","LU1571399168.USD","BK4585"],"gpt_icon":0},{"id":"2586260938","title":"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260938","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260938?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:05","pubTimestamp":1764191100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUAC6HTF5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","BK4539","BK4588","VERA"],"gpt_icon":0},{"id":"2586825074","title":"Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept’s Commercial Potential and Favorable Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586825074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586825074?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:55","pubTimestamp":1764165321,"startTime":"0","endTime":"0","summary":"In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Vera Therapeutics, with a price target of $90.00. Arthur ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-vera-therapeutics-driven-by-atacicepts-commercial-potential-and-favorable-valuation-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-vera-therapeutics-driven-by-atacicepts-commercial-potential-and-favorable-valuation-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":0.1091},{"period":"1month","weight":0.6023},{"period":"3month","weight":1.0951},{"period":"6month","weight":1.19},{"period":"1year","weight":0.104},{"period":"ytd","weight":0.1776}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.108417},{"month":2,"riseRate":0.5,"avgChangeRate":0.034073},{"month":3,"riseRate":0.5,"avgChangeRate":-0.056274},{"month":4,"riseRate":0,"avgChangeRate":-0.100599},{"month":5,"riseRate":0.25,"avgChangeRate":-0.061241},{"month":6,"riseRate":0.4,"avgChangeRate":0.164504},{"month":7,"riseRate":0.8,"avgChangeRate":0.137629},{"month":8,"riseRate":0.6,"avgChangeRate":0.019112},{"month":9,"riseRate":0.6,"avgChangeRate":0.088867},{"month":10,"riseRate":0.2,"avgChangeRate":-0.071412},{"month":11,"riseRate":0.8,"avgChangeRate":0.292871},{"month":12,"riseRate":0.6,"avgChangeRate":0.073143}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}